REGENXBIO (NASDAQ:RGNX) Price Target Cut to $30.00 by Analysts at HC Wainwright

REGENXBIO (NASDAQ:RGNX) had its price objective lowered by HC Wainwright from $32.00 to $30.00 in a research report released on Monday morning,Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock.

A number of other analysts have also weighed in on the stock. Leerink Partners increased their price objective on shares of REGENXBIO from $16.00 to $20.00 and gave the stock an “outperform” rating in a research note on Monday, December 15th. Chardan Capital decreased their target price on shares of REGENXBIO from $52.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, February 10th. Morgan Stanley lowered their price target on shares of REGENXBIO from $18.00 to $17.00 and set an “overweight” rating on the stock in a report on Thursday. Barclays started coverage on REGENXBIO in a research report on Tuesday, January 27th. They set an “overweight” rating and a $37.00 price target on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of REGENXBIO in a research note on Thursday, January 22nd. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, REGENXBIO has a consensus rating of “Moderate Buy” and an average price target of $27.50.

REGENXBIO Stock Up 20.0%

REGENXBIO stock opened at $10.38 on Monday. The stock has a 50-day moving average price of $11.39 and a 200 day moving average price of $11.46. The company has a market capitalization of $535.71 million, a price-to-earnings ratio of -2.76 and a beta of 1.08. REGENXBIO has a 52 week low of $5.03 and a 52 week high of $16.19.

REGENXBIO (NASDAQ:RGNX) last posted its quarterly earnings results on Thursday, March 5th. The biotechnology company reported ($1.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.29). REGENXBIO had a negative return on equity of 103.12% and a negative net margin of 113.75%.The business had revenue of $30.34 million for the quarter, compared to analysts’ expectations of $45.48 million. Research analysts anticipate that REGENXBIO will post -4.84 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. raised its position in REGENXBIO by 4.8% during the third quarter. JPMorgan Chase & Co. now owns 4,037,248 shares of the biotechnology company’s stock worth $38,959,000 after acquiring an additional 185,223 shares during the period. Voss Capital LP increased its stake in shares of REGENXBIO by 47.4% during the second quarter. Voss Capital LP now owns 575,000 shares of the biotechnology company’s stock worth $4,721,000 after purchasing an additional 185,000 shares in the last quarter. Assenagon Asset Management S.A. raised its position in shares of REGENXBIO by 23.2% during the 3rd quarter. Assenagon Asset Management S.A. now owns 705,403 shares of the biotechnology company’s stock worth $6,807,000 after purchasing an additional 132,942 shares during the last quarter. Squarepoint Ops LLC lifted its stake in REGENXBIO by 2,049.0% in the 2nd quarter. Squarepoint Ops LLC now owns 219,288 shares of the biotechnology company’s stock valued at $1,800,000 after buying an additional 209,084 shares in the last quarter. Finally, Rockefeller Capital Management L.P. acquired a new stake in REGENXBIO in the 2nd quarter worth about $220,000. Hedge funds and other institutional investors own 88.08% of the company’s stock.

Key Headlines Impacting REGENXBIO

Here are the key news stories impacting REGENXBIO this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating while trimming its price target from $32 to $30, signaling continued analyst conviction in REGENXBIO’s long‑term upside despite the cut. Benzinga
• Neutral Sentiment: Sector news: uniQure’s shares jumped after the departure of an FDA gene‑therapy official — a development that can lift sentiment across gene‑therapy peers like RGNX but does not relate to any REGENXBIO-specific regulatory event. uniQure sector news
• Neutral Sentiment: Analyst/coverage notes and earnings call transcripts remain available for investors evaluating the story and pipeline; these provide context but are not new catalysts. Analyst insights
• Negative Sentiment: Multiple law firms have filed notices and are soliciting lead plaintiffs in a securities class action against REGENXBIO covering Feb 9, 2022–Jan 27, 2026, with an April 14, 2026 deadline to seek lead‑plaintiff status. The wave of filings (Faruqi & Faruqi; Rosen; Bronstein Gewirtz & Grossman; Portnoy Law Firm, etc.) increases legal overhang and potential future liability or settlement risk for RGNX.
  Faruqi notice
  Rosen notice
  Bronstein notice
  Portnoy notice
• Negative Sentiment: REGENXBIO’s recent Q4/2025 results and transcript show an EPS miss (reported -$1.30 vs. -$1.01 expected) and revenue shortfall; lingering financial underperformance and negative margins remain a headwind for valuation and near‑term sentiment. Earnings transcript

About REGENXBIO

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.